US equities |
SPCX $166.94 ▲+5.02% NVDA $236.90 ▲+1.26% MU $1,064.16 ▼-1.00% TSLA $377.28 ▲+1.81% MSFT $526.49 ▲+1.73% SNDK $1,712.54 ▼-0.43% INTC $117.34 ▼-1.67% META $745.03 ▲+2.33%
FinancialContent

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

15.73 -0.10 (-0.63%)
Delayed Quote Updated: 11:58 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia to Participate in Upcoming Investor Healthcare Conferences
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 15, 2024 ↗
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
News headline image
Earnings Outlook For Aurinia Pharmaceuticals ↗
 
Via Benzinga
News headline image
Why Aurinia Pharmaceuticals Stock Is Slumping Today ↗
The biotech's premium valuation doesn't seem to be sitting well with investors. 
Via The Motley Fool
News headline image
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings. 
Via Benzinga
News headline image
Aurinia Pharmaceuticals Finds No Buyer After Strategic Business Review, Launches Stock Buyback ↗
Aurinia Pharmaceuticals Q4 2023 results: EPS loss $(0.19), sales $45.1 million. AUR200 development halted. Strategic review concludes. $150 million share buyback initiated. 
Via Benzinga
News headline image
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
What's Going On With Aurinia Pharmaceuticals Stock? ↗
Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) shares are trending on social media Friday. The company provided its preliminary, unaudited fourth-quarter and fiscal year 2023 financial results. What To... 
Via Benzinga
News headline image
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Submits IND Application to US Food & Drug Administration for AUR 200
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
What's Going On With Aurinia Pharmaceuticals Stock? ↗
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading higher, adding to gains of more than 17% over the last week. 
Via Benzinga
News headline image
Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
This Oil Giant Is 'Not Great, Not Bad,' But Jim Cramer Says 'I'm Sticking With My Coterra' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said BP (NYSE: BP) is "not great, not bad." He added, "This whole group is going through a real re-evaluation. 
Via Benzinga
News headline image
Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday ↗
The biotech's board is exploring strategic alternatives to boost shareholder value. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >